drugset / Trial / NCT02608242

PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin

NCT02608242

Phase 1 Terminated 123 enrolled Yuhan Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Randomized, open-label, single-dose, 3-treatment, 3-period, 3-sequence crossover design.

Timeline

Start
2015-11
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 10 mg Oral
Comparator Rosuvastatin Small molecule 20 mg Oral
Comparator Telmisartan Other / unclassified 80 mg Oral
Subject YH22189 Unknown Oral